Mp04-17 Blood-Based Biomarkers as Predictors of Oncologic Outcomes for Non-Muscle-Invasive Urothelial Bladder Carcinoma

Chade, Daher C.; Machado, Alex Martins; Waksman, Ricardo; Garcia, Guilherme; Esteves, Patricia; Adonias, Sanarelly Pires; Areas, Flavio G.M.; Botelho, Luis; Cordeiro, Maurício; Murta, Cláudio Bovolenta; Ribeiro-Filho, Leopoldo; Sarkis, Álvaro S.; Shariat, Shahrokh F.; Bastos, Diogo Assed; Dzik, Carlos; Srougi, Miguel; Nahas, William C.

doi:10.1016/j.juro.2017.02.155

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These blood-based biomarkers were taken from 328 patients before TURBT. They found that CEA and CA 19-9 levels were significantly higher in patients who had a recurrence and/or progression compared to those who had no recurrence-CA125 did not differ between the two groups after a mean follow-up of 4.9 years [11]. The authors concluded that further larger future studies should consider including these biomarkers in a predictive model.…”

Section: Biomarkersmentioning

confidence: 96%

Did the Scientific Innovations in the Management of Non-Muscle Invasive Bladder Cancer Patients Improve the Outcome during the Last 2 Decades?

Alame¹,

Raad²,

Ibrahim³

2022

OJU

View full text Add to dashboard Cite

Objectives: Previous reviews reported the outcome of each scientific modality in the management of T1 high-grade bladder cancer. The objective of this review is to assess and evaluate the available scientific modalities used during the last two decades and determine whether they were able to improve the clinical outcome. Literature Search Methodology: A systematic literature review was conducted from 2000-2020 using PubMed, Medline, Embase, and other database sites looking at randomized controlled trials (RCTs), clinical trials, research, review articles, and original articles addressing the different scientific modalities used to diagnose and manage patients with non-muscle invasive Bladder cancer (NMIBC)during the last 2 decades. More than 573 studies were retrieved following the preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and PICOS criteria (Population, Intervention, Comparators, Outcomes, and Study design). Only 85 articles were selected for review including 19 prospective trials, 44 RCTs, original articles, research articles, one review article, and clinical trials-Retrospective studies were excluded to limit bias as much as possible in the analysis. Results: Randomized controlled trials (RCTs) have become the gold standard for evaluating the efficacy of new treatments. They are considered the highest standard of evidence-based medicine and are the method of choice. Overall, we selected 85 studies for review, among them 63 prospective trials and RCTs, with a total of 21,895 patients, published between 2000 and 2020. Previously conducted studies have shown that identifying rare histological types with poor prognoses can help improve outcomes, mainly the plasmacytoid How to cite this paper: Alame, W.F., Raad, N. and Ibrahim, S. (2022) Did the Scientific Innovations in the Management of Non-Muscle Invasive Bladder Cancer Patients Improve the Outcome during the Last 2 Decades?

show abstract

Section: Biomarkersmentioning

confidence: 96%